ClinicalTrials.gg
SuspendedNCT04056741Updated Nov 1, 2023

Administration of Surfactant Through an Instillation Device Infasurf® (Calfactant) in Neonates- A Pilot Study

A Phase 2 interventional study of surfactant airway device in RDS of Prematurity, Surfactant Protein B Deficiency and Chronic Lung Disease, sponsored by ONY. Suspended at 4 sites in United States. Open to participants aged 24 Weeks and older. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by ONY · Phase 2, Interventional, and Treatment

How we know

Why this study was suspended
alteration of study required

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
24 Weeks and older
Sex
All
01

Study summary

A pilot study to explore and determine feasibility and safety of the administration of surfactant through a new supraglottic device in patients from 500 to 5000 grams with RDS.

Read the detailed description

Surfactant therapy can be life-saving for newborn infants with respiratory distress due to surfactant insufficiency, also known as respiratory distress syndrome (RDS). All commercially available surfactants for clinical use are approved for administration through an endotracheal tube. Placement of an endotracheal tube, a procedure called intubation, is stressful for the infant and associated with significant adverse effects. The proposed supraglottic instillation device allows infants to benefit from surfactant therapy while avoiding the negative effects of intubation.

02

Conditions studied

  • RDS of Prematurity
  • Surfactant Protein B Deficiency
  • Chronic Lung Disease

Keywords

  • Neonatal RDS
  • RDS
  • Surfactant Deficiency
03

In context

Respiratory Distress Syndrome In Premature Infants

34 studies on the registry are indexed under Respiratory Distress Syndrome In Premature Infants; 10 are open to participants now.

This study's planned enrollment of 55 is above the median of 45 across 29 interventional studies indexed under Respiratory Distress Syndrome In Premature Infants.

Browse Respiratory Distress Syndrome In Premature Infants studies →

Lead sponsor

ONY is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Weeks and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age at the time of enrollment ≥ 24 0/7 weeks
  • Weight at the time of enrollment 500- 5000 grams
  • Age ≤ 24 hours old
  • Require non-invasive respiratory support (i.e. continuous positive airway pressure, high flow nasal cannula or non-invasive ventilation)
  • Require FiO2 ≤ 40%
  • Clinical diagnosis of RDS

Exclusion criteria

Exclusion Criteria:

  • Prior surfactant administration
  • Prior mechanical ventilation
  • Major congenital anomaly
  • Abnormality of the airway
  • Respiratory distress secondary to an etiology other than RDS (suspected pulmonary hypoplasia, pneumothorax, meconium aspiration syndrome, pneumonia, septic or hypovolemia shock, hypoxic ischemic encephalopathy)
  • Apgar score \< 5 at 5 minutes of age
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Surfactant administered via supraglottic administration device

    Patients in this group will have Calfactant at 3ml/kg administered via the supraglottic administration device.

    Combination Product: surfactant airway device

Interventions

  • Combination productsurfactant airway device

    Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.

06

What researchers measure

Primary outcomes

  1. Instillation failures

    Instillation failure is defined as a lack of clinical response

    Time frame: First 10 minutes after surfactant instillation.

  2. Treatment failure

    "Treatment failure" defined as requiring intubation and liquid surfactant instillation with or without mechanical ventilation.

    Time frame: First 3 days of life

Secondary outcomes

  1. Clinical response

    Duration of oxygen therapy

    Time frame: 3 days

  2. Clinical response

    duration of non-invasive respiratory therapy

    Time frame: 3 days

  3. Clinical response

    number of rescue surfactant doses

    Time frame: 3 days

  4. Clinical response

    incidence of pulmonary air leak

    Time frame: 3 days

  5. Clinical response

    pulmonary hemorrhage

    Time frame: 3 days

  6. Clinical response

    chronic lung disease

    Time frame: defined as need for oxygen at 36 weeks post menstrual age

07

Study locations

4 sites
  • Sharp Mary Birch Hospital for Women & Newborns
    San Diego, California 92123, United States
  • Johns Hopkins All Children's Hospital
    Saint Petersburg, Florida 33701, United States
  • Sisters of Charity Hospital
    Buffalo, New York 14214, United States
  • Jackson-Madison County General Hospital
    Jackson, Tennessee 38301, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for Dec 2025, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2019
First posted
Aug 14, 2019
StartEst.
Feb 7, 2025
Primary completionEst.
Dec 12, 2025
CompletionEst.
Mar 12, 2026
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04056741
Lead sponsor
ONY
Responsible party
Sponsor
First posted
Aug 14, 2019
Start date
Feb 7, 2025 (estimated)
Primary completion
Dec 12, 2025 (estimated)
Completion
Mar 12, 2026 (estimated)
Last update
Nov 1, 2023

Study contacts

Kari Roberts, MD
study chair · Kari Roberts, MD - University of Minnesota, Minneapolis, MN

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion